Abeome is actively looking for partners interested in leveraging the company’s DiSH technology to enable accelerated pre-clinical identification and screening of monoclonal antibody targets. Our strategy encompasses licensing the platform technology to leading pharmaceutical/biotech companies, offering fee-for-service antibody generation, and co-developing our own mAbs for key therapeutic and diagnostic applications.
Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).
Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).
For additional information, please contact Rick Shimkets at (706) 844-2575.
